NeuroNascent: Neuronascent to Present New Parkinson's Model Data at AAIC 2023 for the Alzheimer's Disease Investigational Therapy, NNI-362

ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer's therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer's Association International Conference (AAIC) to be held in Amsterdam, Holland, on July 19, 2023. The main intent of this Parkinson's model work was to assess the capacity of NNI-362, to regenerate neurons and ameliorate behavioral deficits for age-related neurodegenerative disorders in those regions of the brain where disease is present. The Phase 1a trials were successfully completed in a healthy aged population in 2021, for Alzheimer's disease, and Neuronascent aims to continue toward Phase 2 proof-of-concept trials for more than one age-related, neurodegenerative indication. Neuronascent's lead neuron regenerative therapy, NNI-362 has demonstrated the ability to promote new neurons in human cell culture and in aging and degenerative models, especially in the very active region of new neuron growth, the hippocampus. This region of the brain, which is involved in learning and memory, is not ...Full story available on Benzinga.com